Euronext Brussels welcomes arGEN-X to its regulated market


Brussels, 10 July 2014 – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies, today celebrated its admission to listing on the regulated market of Euronext Brussels.

arGEN-X focuses on the discovery and development of human antibodies using its proprietary SIMPLE Antibody (TM) platform. The platform generates a limitless source of extremely high quality human antibodies that modulate the function of disease targets, including complex receptors and highly conserved targets, that are not possible to generate with other antibody technologies. The Lead antibodies generated are further differentiated through enhancement of their cell killing properties (Potelligent® technology) and circulation time in the body (NHance™ technology). arGEN-X’s portfolio consists of novel programs addressing oncology, autoimmune and inflammation indications.

The IPO offer price of arGEN-X (ticker code: ARGX) on Euronext Brussels was at €8.50 per share. arGEN-X issued 4,705,882 new shares equivalent to €40 million. Additionally, an over-allotment option to subscribe to up to 470,589 additional new shares at the Offer Price, equivalent to €4 million, was granted to cover over-allotments or short positions, if any. If the over-allotment option is exercised in full, the total amount of the capital increase will amount to €44 million. The approximate market capitalization of arGEN-X at listing will be €131.7 million.

We are delighted to welcome arGEN-X to Euronext Brussels. arGEN-X’s listing will give it access to Europe’s largest pool of liquidity and will substantially raise its visibility with national and international investors. We look forward to a long-standing partnership with the company and its shareholders,” declared Vincent Van Dessel, CEO of Euronext Brussels.

“The successful IPO of arGEN-X confirms the leading status of Euronext as Europe’s number 1 venue for life sciences companies, in terms of operations and money raised,” said Alain Baetens, Head of Listings of Euronext Brussels. “We are particularly proud of the biotech franchise listed on Euronext Brussels, representing in total over € 1.7 billion of market capitalization. It is of the utmost importance that companies such as arGEN-X can access the financial markets in order to valorise the innovative activities they develop. arGEN-X will benefit from Euronext’s wide range of commercial services and a broad investor reach through a deep pool of liquidity.”

Tim van Hauwermeiren, CEO of arGEN-X, said : “The funds that we have raised through our successful IPO from investors in Europe and the US will enable arGEN-X to advance the clinical development of our differentiated therapeutic antibody candidates, ARGX-110, ARGX-111 and ARGX-113 in orphan diseases. This strategy is designed to yield clinical data demonstrating their therapeutic utility for treating cancer and severe autoimmune diseases, and this data will be leveraged to partner these therapeutic antibodies for development and commercialization across a number of major indications in these areas. The funds will also allow us to further develop and enhance our SIMPLE Antibody™ platform and suite of complementary antibody technologies on which our pipeline of differentiated therapeutic antibodies has been created. We believe that this approach will allow arGEN-X to become an important player in the fast growing therapeutic antibody market and to generate significant value for its shareholders in a timely and efficient manner.”

To celebrate the listing, Tim van Hauwermeiren, CEO of arGEN-X, together with co-founders Torsten Dreier and Hans de Haard, rang the bell to open trading on Euronext’s European markets. They were accompanied by Vincent Van Dessel, CEO of Euronext Brussels, and Alain Baetens, Head of Listings of Euronext Brussels.

KBC Securities and Kempen & Co acted as Joint Global Coordinators and Joint Bookrunners, Petercam as Co-Lead Manager, and Wedbush PacGrow Life Sciences as Selling Agent.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.